

April 15, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUOPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	---

Dear Sir / Madam,

Sub: Execution of an additional product schedule with Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) by TheraNym Biologics Private Limited, a subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

TheraNym Biologics Pvt. Ltd., a subsidiary of Aurobindo Pharma Ltd, announces the addition to the existing CMO Agreement with Merck Sharp & Dohme Singapore Trading Pte Ltd, Singapore, (MSD) by execution of an additional product schedule. This serves to further expand the existing CMO relationship initiated pursuant to the previously disclosed arrangement in May 2024. Under this newly signed product schedule, TheraNym Biologics will construct greenfield project for commissioning a large scale mammalian Drug Substance manufacturing facility (“Unit 2”) housing a total of 60 KL bioreactor capacities.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure A’.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl: as above.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure -A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Description
i	Name of the entity(ies) with whom agreement/ JV is signed	TheraNym Biologics Private Limited, a subsidiary of the Company (TheraNym), signed an additional product schedule with Merck Sharpe & Dohme Singapore Trading Pte. Ltd., Singapore (MSD).
ii	Area of agreement/JV	TheraNym announces the execution of an additional product schedule with MSD, which serves to further expand the existing relationship initiated pursuant to the previously disclosed arrangement in May 2024. The aforesaid agreement pertains to the construction and commissioning of a Drug Substance manufacturing facility (“Unit 2”) as a greenfield project. TheraNym Unit 2 shall encompass the installation of mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce Drug Substance.
iii	Domestic/international	Both domestic & international
iv	Share exchange ratio / JV ratio	Not applicable
v	Scope of business operation of agreement / JV	To further expand the existing relationship initiated in May 2024 in contract manufacturing operations (CMO) for biologicals.
vi	Details of consideration paid / received in agreement / JV	Not applicable
vii	Significant terms and conditions of agreement / JV in brief	TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement.
viii	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

ix	Size of the entity(ies);	Theranym will invest around USD 150 to 175 million for establishing manufacturing facility of mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce Drug Substance.
x	Rationale and benefit expected.	To further expand the existing relationship initiated in May 2024's contract manufacturing operations (CMO) for biologicals.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com